Notification

🚨 Trading Holiday 🚨

The NSE and BSE will remain closed for trading and settlement on Monday, April 14, 2025, on account of Dr. B. R. Ambedkar Jayanti.

Open a Free Demat Account

Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.

Trade Now, Pay Later with up to 4x

Never miss a good trading opportunity due to low funds with our MTF feature.

Track Market Movers Instantly

Stay updated with real-time data. Get insights at your fingertips.

NSE BSE

Trade Nowopens in a new tab

Mstc Limited Share Price

₹ 523.1 23.09 (4.61%)

Apr 15 2025 03:30 PM E-Commerce/App based Aggregator NSE: MSTCLTD

Mstc Limited Share Price Update

As of the latest trading session, Mstc Limited share price is currently at 523.1, which is up by 23.09 from its previous closing. Today, the stock has fluctuated between 505.35 and 527.00. Over the past year, Mstc Limited has achieved a return of -44.16 %. In the last month alone, the return has been 7.28 %. Read More...

Mstc Limited Performance

Day Range

Low505.35 High527.00

523.10

52 Week Range

Low 411.10 High 1036.90

523.10

Mstc Limited Share Price

9356

542597

MSTCLTD

Compare to down-arrow

View

Display

Studies

No Data Available

Open Price

509.95 Prev. Close

500.00 Volume (Shares)

190530.00

Total traded value

996.66 Upper Circuit

600.00 Lower Circuit

400.00

Note: The current prices & values are delayed, Loginopens in a new tab to your account for live updates.

Mstc Limited Fundamentals

(Standalone)

Market Cap (Cr)	3682.62
PE Ratio (TTM)	9.90
Book Value / Share	101.37
Beta	1.61

ROE	27.32%
EPS (TTM)	21.44
Dividend Yield	3.10%
Net Profit Qtr (Cr)	252.43

Mstc Limited Financials

Key Results
Key Ratios
Balance sheet
Cash Flow
Competition

Revenue

Net income

Particulars	DEC 2024 (Values in Cr)
Revenue	81.14
Operating Expense	34.35
Net Profit	252.43
Net Profit Margin (%)	311.10
Earnings Per Share (EPS)	35.86
EBITDA	339.31
Effective Tax Rate (%)	25.16

Particulars	SEP 2024 (Values in Cr)
Revenue	71.92
Operating Expense	34.31
Net Profit	43.02
Net Profit Margin (%)	59.81
Earnings Per Share (EPS)	6.11
EBITDA	59.76
Effective Tax Rate (%)	24.55

Particulars	JUN 2024 (Values in Cr)
Revenue	69.04
Operating Expense	31.53
Net Profit	40.46
Net Profit Margin (%)	58.60
Earnings Per Share (EPS)	5.75
EBITDA	56.88
Effective Tax Rate (%)	25.73

Particulars	MAR 2024 (Values in Cr)
Revenue	81.93
Operating Expense	135.24
Net Profit	19.51
Net Profit Margin (%)	23.81
Earnings Per Share (EPS)	2.77
EBITDA	70.41
Effective Tax Rate (%)	71.24

Particulars	DEC 2023 (Values in Cr)
Revenue	70.85
Operating Expense	37.31
Net Profit	39.33
Net Profit Margin (%)	55.51
Earnings Per Share (EPS)	5.59
EBITDA	59.34
Effective Tax Rate (%)	31.75

Particulars	MAR 2024 (Values in Cr)
Revenue	316.25
Operating Expense	234.85
Net Profit	171.91
Net Profit Margin (%)	54.35
Earnings Per Share (EPS)	24.42
EBITDA	292.17
Effective Tax Rate (%)	39.55

Particulars	MAR 2023 (Values in Cr)
Revenue	324.72
Operating Expense	184.52
Net Profit	239.23
Net Profit Margin (%)	73.67
Earnings Per Share (EPS)	33.98
EBITDA	319.98
Effective Tax Rate (%)	23.68

Particulars	MAR 2022 (Values in Cr)
Revenue	470.64
Operating Expense	529.53
Net Profit	200.05
Net Profit Margin (%)	42.50
Earnings Per Share (EPS)	28.42
EBITDA	227.38
Effective Tax Rate (%)	9.08

Particulars	MAR 2021 (Values in Cr)
Revenue	427.74
Operating Expense	524.44
Net Profit	101.07
Net Profit Margin (%)	23.62
Earnings Per Share (EPS)	14.36
EBITDA	124.05
Effective Tax Rate (%)	11.86

Particulars	MAR 2020 (Values in Cr)
Revenue	830.71
Operating Expense	762.72
Net Profit	75.20
Net Profit Margin (%)	9.05
Earnings Per Share (EPS)	10.68
EBITDA	158.99
Effective Tax Rate (%)	41.92

Particulars	MAR 2024 (Values in Cr)
Book Value / Share	126.28
ROE %	24.39
ROCE %	31.26
Total Debt to Total Equity	0.17
EBITDA Margin	48.59

Particulars	MAR 2023 (Values in Cr)
Book Value / Share	111.72
ROE %	31.44
ROCE %	32.10
Total Debt to Total Equity	0.20
EBITDA Margin	48.71

Particulars	MAR 2022 (Values in Cr)
Book Value / Share	92.90
ROE %	26.45
ROCE %	23.32
Total Debt to Total Equity	0.25
EBITDA Margin	29.28

Particulars	MAR 2021 (Values in Cr)
Book Value / Share	79.25
ROE %	15.01
ROCE %	13.64
Total Debt to Total Equity	0.40
EBITDA Margin	20.82

Particulars	MAR 2020 (Values in Cr)
Book Value / Share	67.32
ROE %	17.01
ROCE %	17.98
Total Debt to Total Equity	1.01
EBITDA Margin	17.29

Particulars	MAR 2024 (Values in Cr)
Book Value / Share	94.40
ROE %	27.32
ROCE %	35.43
Total Debt to Total Equity	0.23
EBITDA Margin	92.41

Particulars	MAR 2023 (Values in Cr)
Book Value / Share	84.38
ROE %	41.23
ROCE %	41.50
Total Debt to Total Equity	0.28
EBITDA Margin	98.56

Particulars	MAR 2022 (Values in Cr)
Book Value / Share	66.11
ROE %	35.31
ROCE %	29.74
Total Debt to Total Equity	0.37
EBITDA Margin	48.36

Particulars	MAR 2021 (Values in Cr)
Book Value / Share	50.42
ROE %	17.84
ROCE %	15.54
Total Debt to Total Equity	0.61
EBITDA Margin	29.18

Particulars	MAR 2020 (Values in Cr)
Book Value / Share	39.75
ROE %	19.42
ROCE %	19.05
Total Debt to Total Equity	1.71
EBITDA Margin	19.23

Particulars	MAR 2024 (Values in Cr)
Cash & Short Term Investments	1148.30
Total Assets	2248.86
Total Liabilities	2248.86
Total Equity	889.04
Share Outstanding	70400000
Price to Book Ratio	8.80
Return on Assets (%)	9.08
Return on Capital (%)	19.76

Particulars	MAR 2023 (Values in Cr)
Cash & Short Term Investments	1600.83
Total Assets	2688.79
Total Liabilities	2688.79
Total Equity	786.50
Share Outstanding	70400000
Price to Book Ratio	3.00
Return on Assets (%)	8.99
Return on Capital (%)	25.97

Particulars	MAR 2022 (Values in Cr)
Cash & Short Term Investments	821.17
Total Assets	2013.90
Total Liabilities	2013.90
Total Equity	654.04
Share Outstanding	70400000
Price to Book Ratio	4.63
Return on Assets (%)	9.88
Return on Capital (%)	24.78

Particulars	MAR 2021 (Values in Cr)
Cash & Short Term Investments	759.71
Total Assets	2247.76
Total Liabilities	2247.76
Total Equity	557.95
Share Outstanding	70400000
Price to Book Ratio	5.92
Return on Assets (%)	5.02
Return on Capital (%)	15.86

Particulars	MAR 2020 (Values in Cr)
Cash & Short Term Investments	233.19
Total Assets	2201.15
Total Liabilities	2201.15
Total Equity	473.92
Share Outstanding	70400000
Price to Book Ratio	1.99
Return on Assets (%)	4.40
Return on Capital (%)	13.24

Particulars	MAR 2024 (Values in Cr)
Cash & Short Term Investments	1029.69
Total Assets	1839.73
Total Liabilities	1839.73
Total Equity	664.57
Share Outstanding	70400000
Price to Book Ratio	8.80
Return on Assets (%)	9.34
Return on Capital (%)	21.24

Particulars	MAR 2023 (Values in Cr)
Cash & Short Term Investments	1439.08
Total Assets	2277.23
Total Liabilities	2277.23
Total Equity	594.02
Share Outstanding	70400000
Price to Book Ratio	3.00
Return on Assets (%)	10.50
Return on Capital (%)	32.37

Particulars	MAR 2022 (Values in Cr)
Cash & Short Term Investments	734.95
Total Assets	1613.94
Total Liabilities	1613.94
Total Equity	465.44
Share Outstanding	70400000
Price to Book Ratio	4.63
Return on Assets (%)	12.39
Return on Capital (%)	32.53

Particulars	MAR 2021 (Values in Cr)
Cash & Short Term Investments	719.86
Total Assets	1849.83
Total Liabilities	1849.83
Total Equity	354.95
Share Outstanding	70400000
Price to Book Ratio	5.92
Return on Assets (%)	5.46
Return on Capital (%)	19.84

Particulars	MAR 2020 (Values in Cr)
Cash & Short Term Investments	171.15
Total Assets	1783.65
Total Liabilities	1783.65
Total Equity	279.83
Share Outstanding	70400000
Price to Book Ratio	1.99
Return on Assets (%)	4.21
Return on Capital (%)	14.7

Particulars	MAR 2024 (Values in Cr)
Net Income	340.17
Cash from Operations	-236.62
Cash from Investing	-244.14
Cash from Financing	-96.44
Net change in Cash	-652.69
Free Cash Flow	-104.72

Particulars	MAR 2023 (Values in Cr)
Net Income	329.17
Cash from Operations	904.70
Cash from Investing	-551.00
Cash from Financing	-118.64
Net change in Cash	174.60
Free Cash Flow	938.55

Particulars	MAR 2022 (Values in Cr)
Net Income	232.90
Cash from Operations	209.88
Cash from Investing	-71.57
Cash from Financing	-98.32
Net change in Cash	0.22
Free Cash Flow	284.27

Particulars	MAR 2021 (Values in Cr)
Net Income	135.88
Cash from Operations	704.58
Cash from Investing	11.23
Cash from Financing	-107.47
Net change in Cash	584.90
Free Cash Flow	740.50

Particulars	MAR 2020 (Values in Cr)
Net Income	166.74
Cash from Operations	256.86
Cash from Investing	255.45
Cash from Financing	-233.16
Net change in Cash	244.53
Free Cash Flow	295.63

Particulars	MAR 2024 (Values in Cr)
Net Income	284.43
Cash from Operations	-222.20
Cash from Investing	-272.04
Cash from Financing	-96.44
Net change in Cash	-651.01
Free Cash Flow	-114.50

Particulars	MAR 2023 (Values in Cr)
Net Income	313.47
Cash from Operations	826.47
Cash from Investing	-474.74
Cash from Financing	-118.64
Net change in Cash	187.30
Free Cash Flow	842.30

Particulars	MAR 2022 (Values in Cr)
Net Income	220.04
Cash from Operations	95.81
Cash from Investing	25.31
Cash from Financing	-98.32
Net change in Cash	-1.87
Free Cash Flow	105.56

Particulars	MAR 2021 (Values in Cr)
Net Income	114.68
Cash from Operations	676.11
Cash from Investing	-9.74
Cash from Financing	-107.22
Net change in Cash	548.27
Free Cash Flow	698.06

Particulars	MAR 2020 (Values in Cr)
Net Income	129.49
Cash from Operations	264.32
Cash from Investing	231.12
Cash from Financing	-230.65
Net change in Cash	233.79
Free Cash Flow	278.36

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
NIHAR INFO GLOBAL LTD.	4.71	0.00	0.52	4.90	4.01 / 7.53
INFO EDGE (I) LTD	6544.75	129.96	2.02	84809.57	5260.00 / 9194.95
INTRASOFT TECH. LTD	98.67	12.68	0.73	160.95	90.00 / 191.40
YAARI DIGI INT SER LTD	14.57	0.00	-0.62	146.34	8.84 / 20.30

Company Name	Price	P/E	P/B	Market Cap	52 Week Low/High
Mitshi India Limited	15.61	0.00	5.09	13.74	13.01 / 36.88
AVI PRODUCTS INDIA LIMITED	19.95	55.42	0.92	6.60	18.25 / 29.29
OLYMPIA INDUSTRIES LTD.	41.24	22.54	0.59	24.84	36.00 / 74.66
ISTREET NETWORK LIMITED	4.69	0.00	-5.44	9.99	1.86 / 5.44

Technicals

EMA & SMA
Resistance and Support
Price Change Analysis

Bullish Moving Averages -

Bearish Moving Averages -

5 Days 498.90
26 Days 501.20
10 Days 500.80
50 Days 522.10
12 Days 500.50
100 Days 575.20
20 Days 499.50
200 Days 632.10

502.60
PIVOT

First Resistance	508.70
Second Resistance	517.40
Third Resistance	523.50

First Support	493.90
Second Support	487.80
Third Support	479.10

RSI	49.49
MACD	-0.62
Commodity Channel Index (CCI)	15.83

ADX	35.87
Williams % R	-55.30

Mstc Limited Future

Future: Price

25 May

0 100 200 300 400 500 600

Discount/Premium

25 May

0 1 2 3 4 5 6 7

Active Calls

25 May

0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul

0 500 1000 1500 2000 2500

Stock Holding

View Live Stock Screeners

Holding

Public

28.09 Promoter Holdings

64.74 FII

5.46 DII

1.68 Promoter Shares(Pledge Percentage)

0.0

Name	Category	Shares	Shares%
President Of India	Shareholding of Promoter and Promoter Group	4.55808E7	64.75
Jupiter India Fund	Public Shareholding	1210034.0	1.72
Valuequest India Moat Fund Limited	Public Shareholding	763798.0	1.08

Mstc Limited

Ex-Date	Dividend Amt.	Dividend Type	Record Date	Instrument Type
2024-02-20	5.0	Interim 2	2024-02-20	Equity shares	2023-11-16	5.5	Interim	2023-11-16	Equity shares	2023-09-12	3.2	Final	2023-09-13	Equity shares	2023-02-22	6.3	Interim 2	2023-02-22	Equity shares	2022-11-18	5.5	Interim	2022-11-21	Equity shares	2022-09-15	4.4	Final	2022-09-16	Equity shares	2022-02-22	6.5	Interim 2	2022-02-23	Equity shares	2021-11-22	2.0	Interim	2021-11-23	Equity shares	2021-09-17	4.4	Final	2021-09-20	Equity shares	2020-09-16	3.3	Final	2020-09-18	Equity shares

Learn More About Stocks

Dr Reddy’s Denies Workforce Reduction Claims Amid Cost-Cut Rumours

Dr Reddy’s Laboratories rejects claims of reducing workforce costs by 25%, asserting no such plans or internal directives.

15 Apr, 2025 | 3 Min. read

Glenmark, Sun Pharma, Zydus Recall Drugs in US over Compliance Issues

Glenmark, Sun Pharma, and Zydus recall multiple drug batches in the US following manufacturing deviations and contamination concerns as per USFDA enforcement reports.

15 Apr, 2025 | 3 Min. read

HAL Denies Selecting PwC for R&D Benchmarking Amid Ongoing Bids

HAL clarifies no consultancy firm has been finalised for R&D benchmarking amid social media buzz about PwC. Selection process still ongoing via GeM portal.

15 Apr, 2025 | 3 Min. read

Aurobindo Pharma Gets USFDA Nod for Generic Xarelto 2.5mg Tablets

Aurobindo Pharma receives USFDA approval to launch generic Xarelto 2.5mg in Q1 FY26, targeting $447 million US market; higher strengths also gain tentative nod.

15 Apr, 2025 | 3 Min. read

IndiGo Becomes World’s Most Valuable Airline With $23.4 Billion Market Cap

IndiGo surpasses global peers to become the most valuable airline by market cap at $23.4 billion, pushing InterGlobe Aviation share price to record highs in 2025.

11 Apr, 2025 | 3 Min. read

SRF Ltd. Commissions New Agrochemical Unit in Dahej Worth Rs.239 Crore

SRF Ltd. starts new agrochemical facility in Dahej, Gujarat with Rs.239 crore investment. Phase 1 operational, full commissioning set for April 2025.

11 Apr, 2025 | 3 Min. read

Tata Motors’ JLR India Achieves Record Sales in FY25 at 6,183 Units

JLR India posts record-breaking FY25 retail sales of 6,183 units, up 40%. Defender leads growth, boosting Tata Motors share price sentiment.

11 Apr, 2025 | 4 Min. read

Biocon Gets USFDA Approval for Jobevne, Expands Oncology Portfolio

Biocon Biologics receives USFDA nod for cancer drug Jobevne, a bevacizumab biosimilar. Oncology portfolio in US grows, boosting Biocon Ltd. share price outlook.

11 Apr, 2025 | 3 Min. read